Apollo Hospitals launches Apollo Research Academy

The Academy, led by Professor Ravi P Mahajan CBE, is set to harmonize the efforts of various Apollo entities

AstraZeneca advances ambition to improve standards of care in multiple cancer types

Presidential Symposium for NIAGARA will highlight practice-changing impact of a perioperative Imfinzi-based regimen in bladder cancer

Finerenone showed statistically significant improvement in cardiovascular outcomes in adults with common form of heart failure

Finerenone is the first mineralocorticoid receptor (MR) antagonist to demonstrate definitive cardiovascular benefits in a Phase III study in patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of ?40%

Zydus receives USFDA final approval for Scopolamine Transdermal System 1 mg/3 days

DKSH partners with Hasten Biopharmaceutical’s growth in Thailand

Indian doctor participates in Jordan’s first robotic radical hysterectomies

Ayurvedic Whole System effective in Managing Rheumatoid Arthritis: Study

The study highlighted substantial improvements in key clinical parameters among RA patients who underwent AWS intervention

Suven Life Sciences announces FDA acceptance of investigational new drug

First-in-human Phase-1 study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SUVN-I6107 in healthy subjects

Bayer starts Phase III trial in non-small cell lung cancer

First patient enrolled in the Phase III SOHO-02 trial of investigational agent BAY 2927088 in treatment-naïve patients with advanced NSCLC with HER2-activating mutations

EC approves Ordspono for the treatment of relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma

Ordspono is Regeneron’s first approved bispecific antibody and will provide an off-the-shelf option that can be administered in the out-patient setting, with hope for complete remission